The Medical Letter on Drugs and Therapeutics
Peramivir (Rapivab): An IV Neuraminidase Inhibitor for Treatment of Influenza
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved peramivir (Rapivab – BioCryst), an IV neuraminidase inhibitor administered as a single dose, for treatment of acute uncomplicated influenza in patients ≥18 years old who have had symptoms for no more than 2 days. Peramivir was available temporarily in the US during the 2009-2010 influenza season under an emergency use authorization for treatment of hospitalized patients. It has been available in some Asian countries since 2010. Peramivir is the third neuraminidase inhibitor to be approved in the US. Oseltamivir (Tamiflu), which is taken orally, and zanamivir (Relenza), which is inhaled, are approved for prophylaxis and treatment of influenza in children and adults.1

TREATMENT OF INFLUENZA — Neuraminidase inhibitors are currently the drugs of choice for treatment of patients with influenza; almost all of the influenza A and B viruses ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Peramivir (Rapivab): An IV Neuraminidase Inhibitor for Treatment of Influenza
Article code: 1461b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian